Details

Autor(en) / Beteiligte

• GLATTRE, E
• THOMASSEN, Y
• THORESEN, S Ø
• HALDORSEN, T
• LUND-LARSEN, P G
• THEODORSEN, L
• AASETH, J

Titel

Prediagnostic Serum Selenium in a Case-Control Study of Thyroid Cancer

Ist Teil von

• International journal of epidemiology, 1989-03, Vol.18 (1), p.45-49

Ort / Verlag

Oxford: Oxford University Press

Erscheinungsjahr

1989

Quelle

MEDLINE

Beschreibungen/Notizen

• Glattre E (Cancer Registry of Norway, Montebello, 0310 Oslo 3, Norway), Thomassen Y, Thoresen S Ø, Haldorsen T, Lund-Larsen P G, Theodorsen L and Aaseth J. Prediagnostic serum selenium in a case-control study of thyroid cancer. International Journal of Epidemiology 1989, 18: 45–49. Sera from 43 persons who developed thyroid cancer on an average 4.8 years after blood sampling were compared with sera from controls. Three controls per case matched for sex, age, place of residence and year of blood sampling, with regard to serum selenium and serum copper. Cases were significantly lower in serum selenium than controls, and the estimated odds ratio of thyroid cancer increased from 1 for levels≥1.65 μmol/l, to 6.1 for levels 1.26–1.64 μmol/l, to 7.7 for levels ≤1.25 μmol/l. When time from blood sampling to diagnosis of the case was considered, it could be shown that the protective effect of high serum selenium concentrations was restricted to the last (<7) years prior to the diagnosis of thyroid cancer. The serum selenium concentration of cases tended to decrease relative to controls the shorter time was from blood sampling to the diagnosis. There was no difference between cases and controls with regard to serum copper.